REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.

Also called NCT01353586

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01353586
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Czechia, Denmark, France, Germany, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01353586. Allocation not applicable; no masking; primary purpose treatment. Start 2011-03-01 (actual); primary completion 2013-09-01 (actual). Results posted on 2016-02-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
Acronym
REVOLUTION
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
nMARQ™ System
Lead sponsor
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01353586
Content hash
2db25ecd2c652c928af4f442c44d4c4e2c579f27e6f1e43cbaff5eeb04870f10